AcuityMD is a commercial intelligence platform empowering medical device companies to identify high-value targets and optimize sales strategies. By integrating data about physicians, care sites, and products from over 325 million patients, AcuityMD's software surfaces insights to drive product adoption and revenue growth. The platform's four core modules - targeting, markets, territories, and pipeline - automate the sales process and unlock data-driven decision making for sales and marketing teams.

AcuityMD was founded in 2019 by Michael Monovoukas, Robert Coe, and Lee Smith. CEO Monovoukas brings industry expertise from his time as a Bain & Company consultant focused on medtech and biopharma commercial strategy. Before AcuityMD, he founded medical device startup Monolysis Medical, an experience he credits with teaching him the fundamentals of selling to healthcare professionals. CTO Coe and Head of Commercial Development Smith round out the founding team with backgrounds in sales engineering and medical device marketing, respectively.

Since raising a $31 million Series A in 2022, AcuityMD has seen significant traction, reporting a 317% increase in ARR and 253% customer growth. The company aims to capture a larger share of the $512 billion global medical devices market by expanding its customer base of sales and marketing teams. Prospective employees have the opportunity to join a fast-growing startup at an inflection point, with the potential to shape the future of medtech commercial intelligence. However, AcuityMD's dependence on the medical devices sector and increasing competition from both direct competitors and larger healthcare data firms pose potential risks to its growth trajectory.